Surgical treatment of “intermediate risk” lymph node negative cervical cancer patients without adjuvant radiotherapy - A retrospective cohort study and review of the literature Journal Article


Authors: Cibula, D.; Abu-Rustum, N. R.; Fischerova, D.; Pather, S.; Lavigne, K.; Slama, J.; Alektiar, K.; Ming-Yin, L.; Kocian, R.; Germanova, A.; Frühauf, F.; Dostalek, L.; Dusek, L.; Narayan, K.
Article Title: Surgical treatment of “intermediate risk” lymph node negative cervical cancer patients without adjuvant radiotherapy - A retrospective cohort study and review of the literature
Abstract: Objectives: The role of adjuvant radiotherapy for lymph node-negative stage IB patients with tumor-related negative prognostic factors is not uniformly accepted. It is advocated based on the GOG 92 trial, which was initiated in 1989. The aim of the current study is to report the oncological outcome of “intermediate risk” patients treated by tailored surgery without adjuvant radiotherapy. Data from two institutions that refer these patients for adjuvant radiotherapy served as a control group. Methods: Included were patients with stage IB cervical cancer treated with radical hysterectomy and pelvic lymphadenectomy, who had negative pelvic lymph nodes but a combination of negative prognostic factors adopted from the GOG 92 trial. Data were obtained from prospectively collected databases of three institutions. Radical surgery was a single-treatment modality in one of them and in the remaining two institutes it was followed by adjuvant chemoradiation. Results: In 127 patients who received only radical surgery, with a median follow-up of 6.1 years, the local recurrence rate was 1.6% (2 cases), and total recurrence was 6.3% (8 cases). Disease-specific survival at 5 years was 95.7% (91.9%; 99.4%) and 91% (83.7%; 98.3%) at 10 years. The only significant factor for disease-specific survival was tumor size ≥4 cm (P = 0.032). The recurrence rate, local control or overall survival did not differ from the control group. Adjuvant radiotherapy was not a significant prognostic factor within the whole cohort. Conclusions: An excellent oncological outcome, especially local control, can be achieved by both radical surgery or combined treatment in stage IB lymph node-negative cervical cancer patients with negative prognostic factors. The substantially better outcome than in the GOG 92 trial can be attributed to more accurate pre-operative and pathological staging and an improvement in surgical techniques. © 2018 Elsevier Inc.
Keywords: adult; cancer chemotherapy; controlled study; cancer surgery; major clinical study; overall survival; cisplatin; multimodality cancer therapy; cancer staging; recurrence risk; follow up; lymph node dissection; pelvis lymph node; progression free survival; tumor volume; pelvis lymphadenectomy; cohort analysis; retrospective study; risk factor; cause of death; uterine cervix cancer; brachytherapy; adjuvant radiotherapy; disease specific survival; radical hysterectomy; chemoradiotherapy; role playing; cancer prognosis; human; female; priority journal; article
Journal Title: Gynecologic Oncology
Volume: 151
Issue: 3
ISSN: 0090-8258
Publisher: Elsevier Inc.  
Date Published: 2018-12-01
Start Page: 438
End Page: 443
Language: English
DOI: 10.1016/j.ygyno.2018.10.018
PROVIDER: scopus
PUBMED: 30348519
DOI/URL:
Notes: Gynecol. Oncol. -- Export Date: 2 January 2019 -- Article -- CODEN: GYNOA C2 - 30348519 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Kaled M Alektiar
    261 Alektiar